Influenza vaccines GRADE assessments

GRADE assessment of influenza vaccines  

High-dose influenza vaccine (Fluzone)

Grade assessment of high-dose influenza vaccine:

• compared with standard dose influenza vaccine in people aged ≥65 years
• compared with adjuvanted influenza vaccine for people aged ≥65 years

Adjuvanted influenza vaccine (Fluad Quad) 

Grade assessment of adjuvanted influenza vaccine:

• compared with standard dose influenza vaccine in adults aged ≥65 years

MDCK cell-derived influenza vaccine (Flucelvax Quad)

Grade assessment of MDCK cell-derived influenza vaccine:

• compared with standard dose egg-based influenza vaccine in children aged 2–17 years
• compared with standard dose egg-based influenza vaccine in people aged ≥18 years

ATAGI recommendations

• Use of high-dose influenza vaccine versus standard dose influenza vaccine in adults aged ≥65 years
• Use of high-dose influenza vaccine versus adjuvanted influenza vaccine in adults aged ≥65 years
• Use of adjuvanted influenza vaccine versus standard dose influenza vaccine in adults aged ≥65 years
• Use of MDCK cell-derived influenza vaccine versus standard dose egg-based influenza vaccine in children aged 2–17 years
• Use of MDCK cell-derived influenza vaccine versus standard dose egg-based influenza vaccine in people aged ≥18 years

Note

These GRADE documents should be read as a supplement to the Australian Immunisation Handbook (Handbook) recommendations.

• View the Influenza disease chapter in the Handbook here
• View the ATAGI advice on seasonal influenza vaccines in 2022 here